Effectiveness of Insulin Glargine on Recovery of Patients with Diabetic Ketoacidosis: A Randomized Controlled Trial

被引:19
作者
Houshyar, Jalil [1 ]
Bahrami, Amir [1 ]
Aliasgarzadeh, Akbar [1 ]
机构
[1] Tabriz Univ Med Sci, Endocrine Res Ctr, Dept Med, Endocrine Sect, Tabriz, Iran
关键词
Diabetes mellitus; Hyperglycemia; Treatment;
D O I
10.7860/JCDR/2015/12005.5883
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Diabetic Ketoacidosis (DKA) is a major hyperglycemic emergency in diabetes mellitus (DM). The basic treatment is injection of Regular insulin (RI). This study was aimed to investigate the effects of insulin Glargine (GI) on recovery of patients with DKA. Materials and Methods: A randomized clinical trial conducted on 40 patients (twenty patients in each group) with DKA. Both groups received standard treatment for DKA. Experimental group was given 0.4U/kg of GI within three hours of initiation of IV insulin infusion. Results: The mean duration of acidosis correction time and recovery from DKA was 13.77 +/- 6.10 and 16.91 +/- 6.49 h in the intervention and control groups respectively (p=0.123). The mean dosage of RI until recovery from DKA was 84.8 +/- 45.6 in the intervention and 116.5 +/- 91.6 units in control groups (p=0.17). Hypokalemia occurred in three patients in intervention and four patients in control groups. In 35% of samples in intervention group and 51% in controls blood sugar was more than 10 mmol/l for 24 h after discontinuation of the insulin infusion (p=0.046). The mean duration of hospitalization was 5.1 +/- 1.88 in intervention and 5.9 +/- 2.19 d in control group (p=0.225). Conclusion: Adding GI to the standard treatment of DKA reduced average time of recovery from DKA, without incurring episodes of hypoglycemia and hypokalemia. This also reduced in the time of recovery from DKA, amount of required insulin and the duration of hospitalization. It seems that the non-significant difference in the time of recovery from DKA be related to the small sample size and study design. Further studies are recommended.
引用
收藏
页码:OC1 / OC5
页数:5
相关论文
共 32 条
[1]  
Alemzadeh R, 2011, NELSON TXB PEDIAT, P1969
[2]  
[Anonymous], 2014, INT DIAB FED
[3]   New approaches to the use of insulin in patients with diabetic ketoacidosis [J].
Barski, Leonid ;
Kezerle, Louise ;
Zeller, Lior ;
Zektser, Miri ;
Jotkowitz, Alan .
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2013, 24 (03) :213-216
[4]   Subcutaneous use of a fast-acting insulin analog - An alternative treatment for pediatric patients with diabetic ketoacidosis [J].
Della Manna, T ;
Steinmetz, L ;
Campos, PR ;
Farhat, SCL ;
Schvartsman, C ;
Kuperman, H ;
Setian, N ;
Damiani, D .
DIABETES CARE, 2005, 28 (08) :1856-1861
[5]  
Doshi PB, 2013, ANN EMERG MED, V62, pS133
[6]  
Eisenbarth G, 2011, WILLIAMS TXB ENDOCRI, P1453
[7]   Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients [J].
Ersöz, HÖ ;
Ukinc, K ;
Köse, M ;
Erem, C ;
Gunduz, A ;
Hacihasanoglu, AB ;
Karti, SS .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (04) :429-433
[8]  
Graves EJ, 1997, VITAL HLTH STAT, V130, P1
[9]  
Greet V, 2008, ACUTE ENDOCRINOLOGY, P123
[10]   Subcutaneous Administration of Glargine to Diabetic Patients Receiving Insulin Infusion Prevents Rebound Hyperglycemia [J].
Hsia, Elisa ;
Seggelke, Stacey ;
Gibbs, Joanna ;
Hawkins, R. Matthew ;
Cohlmia, Elizabeth ;
Rasouli, Neda ;
Wang, Cecilia ;
Kam, Igal ;
Draznin, Boris .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (09) :3132-3137